Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF Sept. 30, 2011 Issue | Archived Issues

Physician News

- Michael J. Alexander, MD
- Mahul B. Amin, MD
- Keith L. Black, MD
- Armando E. Giuliano, MD

» Read more


Meetings and Events


Grand Rounds

Click here to view upcoming Grand Rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - September 2011 (PDF)

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Cedars-Sinai Opens Induced Pluripotent Stem Cell Core Production Facility

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

Cells produced by the Cedars-Sinai core - one of the first to open in California - will be used in research funded by the National Institutes of Health and the California Institute for Regenerative Medicine. The cells will be critical for innovative research aimed at increasing our understanding of human diseases and genetic disorders, and the quest for new treatments.

"The opening of the Cedars-Sinai Stem Cell Core Facility underscores what an exciting time this is in regenerative medicine," said Shlomo Melmed, MD, senior vice president of academic affairs and dean of the faculty at Cedars-Sinai. "It also is an example of Cedars-Sinai's deep commitment to the scientific research that will be translated into tomorrow's leading-edge treatments."

The new facility will use the latest technology to generate induced pluripotent stem cells from a patient skin scraping. The induced pluripotent stem cells can be replicated indefinitely and have biological properties similar to embryonic stem cells. These "blank slate" cells can then be turned into any kind of differentiated cell, such as a brain cell or an eye cell or a liver cell.

Although iPS cells were first produced only three years ago, they have quickly become valuable research tools. Clinicians can take skin cells from patients with specific life-threatening diseases. Then, Regenerative Medicine Institute scientists can create iPS cells from them and generate so-called "disease in a dish" models that enable them to more easily identify effective therapies.

"Now, for the first time, we can study human diseases by creating a laboratory specimen of afflicted cells," said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute. "We have been funded by both the National Institutes of Health and the California Institute of Regenerative Medicine to do this work, which has the potential to revolutionize medicine."

For example, the Stem Cell Core Facility already is supplying iPS cells to a five-member NIH consortium of researchers for development of potential therapies to treat Huntington's disease, an incurable neurodegenerative genetic disorder that affects muscle coordination and some cognitive functions, such as memory. With funding from the California Institute for Regenerative Medicine, the Cedars-Sinai core has also generated iPS cells from children with spinal muscular atrophy - a lethal disease that leaves children paralyzed. These are being used to develop novel drug compounds to treat this devastating disorder,

"We are very excited to launch this new core facility," said Dhruv Sareen, PhD, the core's new director. "It will enable exciting studies across the entire Cedars-Sinai Medical Center and we look forward to much productive collaboration."